B–O Bond Reinforced Mechanical Stability of Alginate-Based Jammed Emulsion for Enhancing Pesticide Droplet Foliar Deposition حسب Yan Zhou (6523)

الموضوعات:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

الموضوعات:

Participant demographic and clinical characteristics. حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... حسب Claire M. Douglas (21238238)

الموضوعات:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... حسب Claire M. Douglas (21238238)

الموضوعات:

B–O Bond Reinforced Mechanical Stability of Alginate-Based Jammed Emulsion for Enhancing Pesticide Droplet Foliar Deposition حسب Yan Zhou (6523)

الموضوعات:

B–O Bond Reinforced Mechanical Stability of Alginate-Based Jammed Emulsion for Enhancing Pesticide Droplet Foliar Deposition حسب Yan Zhou (6523)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... حسب Claire M. Douglas (21238238)

الموضوعات:

B–O Bond Reinforced Mechanical Stability of Alginate-Based Jammed Emulsion for Enhancing Pesticide Droplet Foliar Deposition حسب Yan Zhou (6523)

الموضوعات:

Socio-demographic and medical characteristics of patients with liver cancer. حسب Ayana Ablayeva (22103708)

الموضوعات:

Data cleaning and preparation algorithm. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. حسب Ayana Ablayeva (22103708)

الموضوعات:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات: